Fig. 3

EDAL attenuates RABV pathogenicity in vivo. a–c Female C57BL/6 mice (8-week-old, n = 10) were infected intranasally with 100 FFU rRABV, rRABV-EDAL, or rRABV-reEDAL, or mock infected. Body weight change (a), clinical score (b), and survival ratio (c) were monitored daily for continuous 3 weeks (means ± SEM; **P < 0.01; body weight change and clinical score was analyzed by two-way ANOVA test; survival ratio was analyzed by log rank test). d At indicated time points, the brains from the infected mice were collected for analyzing the level of RABV N mRNA by qPCR (n = 5; means ± SEM; **P < 0.01 by Student’s two-way ANOVA test). e, f At 12 dpi, the brains were collected, resolved by paraffin sections, and analyzed by immunohistochemistry by staining with antibodies against RABV P (e) or CD45 (f). Scale bar, 50 μm